Sagimet Q3 Loss Widens to $19.1M as AURORA Phase 3 Ramps; $275.8M Cash Plus $107.5M October Net
SGMT has more than doubled off its 52-week low of $4.5.
Summary
Sagimet's Q3 2026 net loss widened to $19.1M on a 68% jump in R&D for the AURORA Phase 3 acne trial, leaving $275.8M in cash and securities before the October offering added about $107.5M net. The ATM was terminated with no shares sold.
Key Events · Earnings and Guidance · SGMT
-
Q3 Loss Widens on Phase 3 Spend
Net loss was $19.1M for Q3 2026 versus $12.9M a year earlier; R&D rose 68% to $16.3M, driven by the AURORA Phase 3 trial and TVB-3567 Phase 1.
-
Liquidity Covers At Least 12 Months
Cash, cash equivalents and marketable securities totaled $275.8M at September 30, 2026, including $27.5M of investor funds received before the October offering closed; management says this plus the October net proceeds funds at least 12 months.
-
October Offering Adds ~$107.5M Net
The October 1, 2026 offering sold 8,750,010 shares at $10.00 and 2,750,010 pre-funded warrants at $9.9999 for about $115.0M gross and an estimated $107.5M net.
-
ATM Terminated With No Sales
The August 2025 at-the-market program, sized at up to $75.0M, was suspended and its prospectus supplement terminated effective September 30, 2026; no shares were sold under it.
Analysis · SGMT · Life Sciences
The wider loss reflects the cost of running a pivotal US Phase 3 acne trial: R&D rose 68% to $16.3M in the quarter. That spending is funded — $275.8M of cash and securities at September 30 plus roughly $107.5M net from the October offering covers at least the next 12 months, so there is no near-term financing need. The trade-off is dilution already taken: the October deal added 8.75M shares at $10.00 plus 2.75M pre-funded warrants, and the ATM was terminated with zero sales. MASH work is parked until non-dilutive money appears, which concentrates the story on AURORA enrollment and the TVB-3567 Phase 2 start before year-end.
How filings like this one have moved
In the 30 days to Nov 11, 2026, 36.6% of the 3434 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SGMT was trading at $11.40 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $802.6M. The 52-week trading range was $4.50 to $11.45. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.